title: Imetelstat therapy in refractory anemia with ring sideroblasts with or without thrombocytosis.
authors.affiliation: Division of Hematology, Mayo Clinic, Rochester, MN, USA.
authors.forename: A
authors.initials: A
authors.lastname: Tefferi
authors.affiliation: Division of Hematology, Mayo Clinic, Rochester, MN, USA.
authors.forename: A
authors.initials: A
authors.lastname: Al-Kali
authors.affiliation: Division of Hematology, Mayo Clinic, Rochester, MN, USA.
authors.forename: K H
authors.initials: KH
authors.lastname: Begna
authors.affiliation: Division of Hematology, Mayo Clinic, Rochester, MN, USA.
authors.forename: M M
authors.initials: MM
authors.lastname: Patnaik
authors.affiliation: Division of Hematology, Mayo Clinic, Rochester, MN, USA.
authors.forename: T L
authors.initials: TL
authors.lastname: Lasho
authors.affiliation: Janssen Research & Development, LLC, Raritan, NJ, USA.
authors.forename: A
authors.initials: A
authors.lastname: Rizo
authors.affiliation: Janssen Research & Development, LLC, Raritan, NJ, USA.
authors.forename: Y
authors.initials: Y
authors.lastname: Wan
authors.affiliation: Division of Hematopathology, Mayo Clinic, Rochester, MN, USA.
authors.forename: C A
authors.initials: CA
authors.lastname: Hanson
mesh_terms: D000753:Anemia, Refractory / Q000150:complications* / Q000175:diagnosis / Q000188:drug therapy* / Q000235:genetics; D000756:Anemia, Sideroblastic / Q000150:complications* / Q000175:diagnosis / Q000188:drug therapy* / Q000235:genetics; D003131:Combined Modality Therapy; D006801:Humans; D007211:Indoles / Q000627:therapeutic use*; D009536:Niacinamide / Q000031:analogs & derivatives* / Q000627:therapeutic use; D009841:Oligonucleotides; D013922:Thrombocytosis / Q000150:complications* / Q000175:diagnosis
chemical_list: D007211:Indoles; D009841:Oligonucleotides; D009536:Niacinamide; C519562:imetelstat